
CureVac (NASDAQ: CVAC)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
CureVac Returns vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
CureVac Company Info
CureVac
News & Analysis
The stock rose for the third consecutive day.
Revisions to a shareholder agreement are causing the German vaccine maker's shares to fall.
The company is throwing in the towel on its first-generation COVID-19 vaccine candidate.
It isn't likely.
CureVac aims to become one of Europe's big suppliers.
Funds will not be safe if invested in this coronavirus stock.
CureVac shares have slipped more than 20% on bad news.
Investors' dreams of a third strong mRNA vaccine may be over.
Valuation
Earnings Transcripts
CVAC earnings call for the period ending March 31, 2022.
CVAC earnings call for the period ending September 30, 2021.
CVAC earnings call for the period ending March 31, 2021.
CVAC earnings call for the period ending September 30, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.